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Abstract
Background: Previous evidence supports the role of noradrenergic systems in ADHD, and norepinephrine
transporter (NET) is critical in regulating the noradrenergic system. The present study aimed to investigate the
association between NET gene polymorphism and the performance measures of the Continuous Performance Test
(CPT) in Korean ADHD children.
Methods: Eighty-seven children (mean age = 9.23 ± 1.99 years) with ADHD were recruited from a university
hospital. Genotypes of G1287A of the NET gene (SLC6A2) were analyzed. All participants completed the CPT, with
performance measures of omission errors, commission errors, reaction time and reaction standardization computed.
The relationship between G1287A polymorphisms and CPT performance measures was examined.
Results: There were 46 subjects with the G/G genotype, 35 subjects with the G/A genotype and 6 subjects with
the A/A genotype. Among the three groups, there were no significant differences in the performance of CPTs.
When dichotomized according to whether the subjects have the rare allele or not, subjects with the homozygous
G/G genotype showed significantly lower commission errors compared to those without G/G genotypes (by
independent T-test, t = -2.18, p = 0.026).
Discussion: Our study found a significant association between commission errors of the CPT and the G1287A
genotype of the NET gene in Korean ADHD children. These findings suggest a protective role of the G/G genotype
of the NET polymorphisms in the deficits of response inhibition in ADHD children.
Background
ADHD is a highly prevalent childhood psychiatric disor-
der that is characterized by inattention, impulsivity and
hyperactivity. Neurobiological studies of ADHD point to
the role of genetic factors with its high heritability esti-
mates [1-3]. Considerable efforts have been made to
investigate the molecular basis of ADHD, with most
investigation on dopaminergic and noradrenergic genes
[4], but results have been variable. One of the reasons
that could explain the lack of consistency in the genetic
studies of ADHD is the great phenotypic heterogeneity
of the disorder. In an effort to overcome the limits of
categorical approach to a highly heterogeneous condi-
tion, the need for investigations of endophenotypes
through quantitative neuropsychological assessments
have been emphasized [5-7].
Continuous performance test (CPT) is one of the most
widely used neuropsychological tests in ADHD. The test
assesses several measures including sustained attention
in response to target stimuli and inhibitory control in
response to non-target stimuli. These measures are con-
tinuously quantifiable and probabilistically predictive of
ADHD [8], with recent meta-analytic review reporting
that the CPT measures possess the largest effect size for
the diagnosis of ADHD [9]. Due to these characteristics,
the measures of CPT have recently been proposed as a
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promising endophenotype for ADHD [8]. Thus far, a
number of studies that investigated the genetic basis of
CPT have mostly focused on dopaminergic genes such as
the dopamine D4 receptor gene [10,11], the dopamine
D5 receptor gene [12] and the dopamine transporter
gene [13]. In these studies, variants of the different dopa-
minergic genes have been associated with measures of
inhibitory control and response time variability on CPT
performance. In contrast, the investigation of the effects
of the noradrenergic system has been relatively scarce.
Several lines of genetic research have suggested the role
of noradrenergic pathways in the pathophysiology of
ADHD. The noradrenergic system is known to be involved
in the modulation of attention and arousal. Its activation
has marked effects on the function of the prefrontal cortex
(PFC), with particular relevance to ADHD [14]. Low to
moderate concentrations of norepinephrine (NE) improves
PFC function, whereas high levels of NE that can be
released during stress are known to impair PFC function
[14]. Clinically, the improvement of ADHD symptoms
with atomoxetine, a highly selective noradrenergic reup-
take inhibitor, supports the significant role of the noradre-
nergic system in the disorder [15,16]. Although no clear
conclusion has been drawn, a number of studies have
reported an association between the norepinephrine trans-
porter gene (SLC6A2) and ADHD [17,18]. The NET
SLC6A2 gene is located on chromosome 16q12.2. with a
genomic structure of 14 exons spanning over 48 kb
[19,20]. Among the different polymorphisms identified for
the NET gene, the G1287A polymorphism at exon 9 has
received attention in relation to ADHD. In a study by
Yang et al. [21], ADHD subjects with the A/A genotype of
the G1287A polymorphism showed less symptom reduc-
tion after treatment with methylphenidate (MPH) com-
pared to those with other genotypes (G/A or G/G
genotypes). Although several other studies that followed
failed to find a significant association between G1287A
polymorphism and ADHD [22,23], a recent study of Kor-
ean ADHD children showed an association between
G1287A polymorphism and MPH response [24].
In regards to the CPT, only a few studies have explored
the association with the NET gene. In a study by Cho et
al. [23], ADHD subjects with the T allele (A/T or T/T
genotypes) of the -3081 polymorphism showed a trend of
higher mean score in response time variability of the
CPT than those with the A/A genotype, while no differ-
ences were found between genotypes of G1287A poly-
morphism in the CPT performance measures. More
recently, Kollins et al. [8] reported a significant associa-
tion between reaction time variability of the CPT and the
NET gene polymorphism (rs3785155) in 364 individuals
from 152 families with at least one child diagnosed with
ADHD. With mixed results, more studies are warranted
to clarify the roles of the noradrenergic systems in the
molecular genetic basis of ADHD. This study aimed to
add to this potentially important part of the literature on
the pathophysiology of ADHD by investigating the asso-
ciation between NET gene polymorphism and the CPT
performance in children and adolescents with ADHD.
Methods
Subjects
Eighty-seven children with ADHD were recruited from a
child psychiatric outpatient clinic in a university hospital
in South Korea. Inclusion criteria were as follows: 1) sub-
jects diagnosed as having ADHD according to the DSM-
IV diagnostic criteria, 2) subjects between the ages of
6-15 years, 3) those who gave informed consent, and 4)
those who have never taken psychostimulants. Exclusion
criteria were as follows: 1) subjects diagnosed with aut-
ism, mental retardation, language difficulties or develop-
mental problem including learning difficulties, 2) those
with a history of a brain damage or seizure disorders,
3) those without an informed consent form from their
parents or guardians. The study was approved by the
Institutional Review Board. Korean version of the Kiddie-
Schedule for Affective Disorder and Schizophrenia Pre-
sent and Lifetime Version (K-SADS-PL) was used as a
diagnostic tool. K-SADS-PL [25] is a semistructured
interview for the psychiatric diagnosis of children. The
Korean version of the K-SADS-PL was translated by Kim
et al., and its validity and reliability have been proved to
be high [26]. We measured the IQ using the WISC III
(Wechsler Intelligence Scale for Children-Third Edition)
[27] - Korean version.
ADHD Rating Scale-IV (ARS)
The ARS is the ADHD symptom severity scale designed
by DuPaul et al. [28] composed of a total of 18 items.
Each item has a 4-point scale from 0 to 3. The 18 items
are composed of 9 items reflecting the symptoms related
with inattention and 9 items reflecting the symptoms
related with hyperactivity and impulsivity. The Korean
version of ARS was standardized.
Continuous Performance Test
All participants completed the computerized CPT. The
Korean version of the CPT used in this study was devel-
oped and standardized by Shin et al. [29]. Subjects went
through a practice run before undertaking the test.
Visual stimuli incorporating shapes were used, and all
scores were automatically recorded in the computerized
test. The test durations for children according to their
age were: 1) ten minutes for those between the ages of
6-7 years, and 2) fifteen minutes for those older than
seven years old. The four measures of omission errors,
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commission errors, the mean reaction time and the
standard deviation of the reaction time (reaction time
variability) were computed.
The details about four indices were as follows: 1)
Number of cases where a response is missed - namely,
omission error, as indicator of inattention; 2) Number
of cases where a response occurs in the presence of
non-target stimuli - these are commission errors, an
indicator of hyperactivity or impulsivity; 3) Mean reac-
tion time that measures the speed of process handling
as a hit response time toward target stimuli; 4) Standard
deviation of reaction time that measures vigilance [29].
The results were converted into values of assessments
on the basis of standard computation from the normal
group of the same age. The measured values were used
for statistical analyses.
Preparation of Genomic DNA and Genotyping
Genomic DNA was extracted from the blood lympho-
cytes of all participants with a genomic DNA extraction
kit (Bioneer, Daejeon, South Korea). Detection of the
SNP was done by the analysis of the primer extension
products generated from the previously amplified geno-
mic DNA using a chip-based Matrix-Assisted Laser
Desorption/Ionization - Time of Flight (MALDI-TOF)
mass spectrometry platform (Sequenom, Inc., CA). The
general methods were performed according to the pro-
tocol of the producer.
Polymerase Chain Reaction (PCR)
PCR primers were generated using the Primer3 program
http://www-genome.wi.mit.edu/cgi-bin/primer/pri-
mer3_www.cgi. The forward and reverse PCR primers
(5’- ACGTTGGATGAGACCCTAATTCCTGCACCC
and 5’- ACGTTGGATGTTCAGGACCTGGAAGT-
CATC) were used to generate PCR products. The PCR
was performed in a volume of final volume of 5 μl con-
taining 1X PCR buffer (TAKARA, Japan), 2.5 mmol/L
MgCl2, 0.2 mmol/L of each deoxyribonucleotide tripho-
sphate (dNTP), 0.1 U HotStar Taq Polymerase (Quiagen
GmbH, Germany), 8 pmol/L of each primers and 4.0 ng
of the genomic DNA. The PCR reaction consisted of the
following processes: denaturation at 95°C for 15 min, 45
cycles of 95°C for 20 sec, 56°C for 30 sec and 72°C for 1
min, with the final extension step at 72°C for 3 min.
Homogeneous Mass EXTEND (hME)
To remove the unincorporated dNTPs, 0.3 U of Shrimp
alkaline phosphatase were added and incubation was
performed for 20 min at 37°C, followed by 5 minutes at
85°C to inactivate enzyme.
The oligonucleotide sequence of the hME extension
primer was 5’- GCATGGAGGCTGTCATCAC, which
was designed manually. We selected the forward or the
reverse DNA strand depending on several factors
including the characteristics of the polymorphism and
the GC content. The final volume of each reaction was
9 μl, containing hME enzyme (Thermosequenase; GE
Healthcare, UK), the termination mix and 5 μmol/L of
the extension primer. The primer extension reaction
was started with the initial denaturation at 94°C for
2 min, followed by 55 cycles of 94°C for 5 sec, 52°C for
5 sec, and 72°C for 5 sec. The reaction product was
desalted with SpectroCLEAN (Sequenom, Inc., CA). The
samples were distributed on 384 well SpectroCHIP
(Sequenom, Inc., CA), using SpectroJET (Sequenom,
Inc., CA). The SpectroCHIPs were analyzed by MALDI-
TOF MassARRAY system (Bruker-Sequenom, CA).
After an overall automatic measurement, assays with
bad peaks were checked manually.
Statistical Analyses
For statistical analyses, one-way analysis of variance
(ANOVA) was used to evaluate the association between
the three genotype groups (G/G genotypes, G/A geno-
types and A/A genotypes) and the four CPT measures.
Due to the small sample size of those with A/A geno-
types, subjects were dichotomized according to whether
they have the rare A allele or not. Independent T-test
was used to compare the differences in the CPT mea-
sures between the two groups. The level of significance
was held at 0.05. All analyses were done by the Statisti-
cal Package for the Social Science (SPSS; SPSS Inc., Chi-
cago, IL, US) for Windows.
Results
Demographic and Clinical Characteristics
Eighty-seven ADHD children were enrolled, consisting
of 72 males (82.8%) and 15 females (17.2%). The mean
age of the ADHD subjects was 9.23 years of age (SD =
1.99), and the average total IQ was 104.79 (SD = 16.2).
Among the 87 ADHD subjects, 39 (44.8%) were classi-
fied as ADHD combined type, 40 (46.0%) as the inatten-
tive type and 8 (9.2%) as the hyperactive/impulsive type.
The average total score of the ADHD symptom rating
scale measured by the parents was 32.26 (SD = 7.91).
There were no significant differences among groups of
G/G, G/A and A/A genotypes in the demographic and
clinical characteristics (Table 1).
Genetic Polymorphisms of SLC6A2
The distribution of the genotypes for SLC6A2 was as
follows: 46 subjects (52.9%) with the G/G genotype, 35
subjects (40.2%) with the G/A genotype and 6 subjects
(6.9%) with the A/A genotype. The results were similar
to the previous studies in Korean ADHD children (Cho
et al.) The distribution of the genotypes was in Hardy-
Weinberg equilibrium.
Song et al. Behavioral and Brain Functions 2011, 7:12
http://www.behavioralandbrainfunctions.com/content/7/1/12
Page 3 of 7
Comparison of the CPT performance between the
subjects with and without G/G genotype
Among the three SLC6A2 genotype groups, there were
no significant differences in the performance of CPTs.
When dichotomized according to whether the subjects
have the rare allele or not, subjects with the homozy-
gous G/G genotype showed significantly lower commis-
sion errors compared to those without G/G genotypes
(by independent T-test, t = -2.18, p = 0.026) (Figure 1).
No significant differences were found in other perfor-
mance measures of the CPT between the two genotypes
(Table 2).
Discussion
Our study found a significant association between com-
mission errors of the CPT and the NET G1287A genotype
in Korean ADHD children. The finding suggests that there
may be a protective role of the G allele regarding the
response inhibition deficit in ADHD. Furthermore, the
results emphasize the possible role of the noradrenergic
system underlying the pathophysiology of ADHD.
The commission errors are an indicator of deficits in
response inhibition. Barkley [30] proposed response
inhibition as the core deficit in ADHD, noting that it is
integral to behavioral regulation and maintenance of
executive function. Our data shows that the NET gene
Table 1 Demographic and clinical characteristics according to SLC6A2 genotype
GG(n = 46) GA(n = 35) AA(n = 6) p
Age 9.22 ± 1.89 9.14 ± 2.17 9.83 ± 1.94 .7381)
Sex .1672)
Male (%) 40(87.0) 26(74.3) 6(100.0)
Female (%) 6(13.0) 9(25.7) 0(0)
IQ 106.87 ± 13.44 100.86 ± 18.31 111.83 ± 20.63 .140 1)
ADHD Subtype
Combined (% of each genotype) 18(39.1) 17(48.6) 4(66.7) .6092)
Inattentive (% of each genotype) 24(52.2) 14(40.0) 2(33.3)
Hyperactive/Impulsive (% of each genotype) 4(8.7) 4(11.4) 0(0)
Comorbidity
CD (% of each genotype) 0(0) 3(5.7) 0(0) .2192)
ODD (% of each genotype) 1(2.2) 1(2.9) 0(0) .9082)
Mood (% of each genotype) 10(21.7) 8(22.9) 0(0) .2622)
Anxiety disorder (% of each genotype) 4(8.7) 5(14.3) 1(11.1) .7422)
Tic (% of each genotype) 7(15.2) 0(0.0) 1(16.7) .0512)
ARS scores
Total 31.72 ± 7.97 32.89 ± 8.08 32.83 ± 7.68 .796 1)
Inattentive 16.74 ± 3.96 16.83 ± 4.44 17.67 ± 3.83 .876 1)
Hyperactivity/impulsivity 14.98 ± 6.81 16.06 ± 6.05 15.17 ± 5.15 .752 1)
1) Data determined using one-way analysis of variance test.
2) Data determined by c2 test or Fisher’s exact test.
ADHD, Attention-deficit hyperactivity disorder; ODD, Oppositional defiant disorder; ARS, ADHD rating scale.
Figure 1
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polymorphism may affect response inhibition deficits in
ADHD, with G/G genotypes presenting less commission
errors. This result is in consistency with the results by
Yang et al. [21] in which ADHD subjects with the G
allele (G/A or G/G genotypes) showed more symptom
improvement compared to those with the A/A genotype
in response to MPH. Together, these findings suggest a
possible protective effect of the G allele in the core defi-
cit of inhibitory control in ADHD.
Atomoxetine selectively increases catecholamine neu-
rotransmission in the prefrontal cortex, without the asso-
ciated effects of psychostimulants on striatal dopamine
transmission. In the study by Chamberlain et al. [31], a
single dose of atomoxetine selectively improved perfor-
mance of inhibitory control, as measured by stop-signal
reaction times in a stop-signal task and commission
errors in the CPT, while deficits of working memory
remained in adults with ADHD. These results were
consistent with the animal studies in which atomoxetine
reduced impulsive responses on the five-choice serial
reaction time test [32] and improved stop-signal reaction
times in rats [33]. Similarly, yohimbine, an alpha-2 adre-
noreceptor antagonist, increased impulsivity as measured
by commission errors in a task derived from CPT in
healthy volunteers [34]. In neuroimaging studies,
abnormalities of the right inferior frontal cortex, which is
known to be associated with inhibitory dysfunction, have
been shown during a test of response inhibition in medi-
cation-naïve adolescents with ADHD [35], while atomox-
etine was shown to increase the activation of this region
in healthy volunteers [36]. Parallel to our results at a
molecular genetic level, these findings implicate the
role of noradrenaline in the modulation of response
inhibition.
In other lines of research, Jonsson et al. [37] reported
that healthy volunteers with the G/G genotype of the
G1287A polymorphism had higher cerebrospinal fluid
(CSF) concentration of the NE metabolite 3-methoxy-4-
hydroxyphenylglycol (MPHG) compared to other geno-
types. The NET is an important component of the
noradrenergic pathway which functions to reuptake NE
into the presynaptic terminals. The reuptake of the
dopamine in the frontal cortex is also primarily done by
the NET. Considering these, abnormalities in the NET
function may lead to perturbed NE and dopamine levels
in the prefrontal cortex, which may in turn lead to the
pathophysiology of ADHD. Furthermore, the heritability
of inhibitory control measures such as the commission
errors have been confirmed in both family-based and
twin studies [38,39]. This indicates that the inhibitory
control deficits associated with the NET gene may be
heritable traits of ADHD patients and their families.
Stober et al. [40] reported that the G1287A polymorph-
ism is a silent mutation with no functional consequences.
Thus, it can be assumed that the variant probably does
not have a direct effect but rather is in linkage disequili-
brium with another causal variant. Kim et al. [41]
reported that the G1287A polymorphism is located near
SNPs, such as rs11679324, rs3285157 and rs998424, that
are associated with ADHD. The authors also reported
that the linkage disequilibrium is very high in these
regions. Moreover, the G1287A polymorphism is located
in exon 9 which encodes an uncharacterized domain of
the protein placed between two transmembrane domains
[40]. Thus, the affinity of the binding or the transport of
neurotransmitters may be affected by this exon.
There are several limitations to be mentioned in our
study. First, although the level of performance of CPT
and the frequencies of the NET polymorphisms in this
study are similar to previous reports, we did not compare
between ADHD subjects and controls on the CPT perfor-
mances and NET polymorphisms. Secondly, the sample
size of the current study was very small, so the results
cannot be generalized to the general population and also
should be carefully interpreted. Thirdly, we did not a
multiple comparison test by independent T-test to com-
pare the four CPT measures between two groups, even
though we performed a multiple comparisons test by
one-way ANOVA to compare the four CPT measures
among three groups. Fourthly, when we performed non-
Table 2 Comparison of four performance measures on CPT according to G1287A genotypes of SLC6A2
Mean (SD) F p-value1) Mean (SD) t p-value 2)
GG
(n = 46)
GA
(n = 35)
AA
(n = 6)
G/G
(n = 46)
G/A +A/A
(n = 41)
Omission errors 66.22
(40.44)
58.89
(18.17)
53.67
(19.71)
.755 .473 66.22
(40.44)
58.12
(18.24)
1.179 .242
Commission errors 61.57
(21.35)
78.80
(42.18)
69.66
(44.06)
2.734 .071 61.57
(21.35)
77.46
(45.02)
-2.260 .026*
Reaction time 56.04
(15.71)
52.86
(10.94)
57.50
(30.59)
.522 .595 56.04
(15.71)
53.54
(14.88)
.764 .447
Reaction time variability 67.33
(25.94)
69.80
(20.51)
75.33
(52.82)
.280 .756 67.33
(25.94)
70.61
(26.65)
-.581 .563
1) By one-way ANOVA, 2) By t-test, CPT: Continuous Performance Test, SD: Standard deviation, * p < 0.05.
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parametric test to evaluate the significance level on two
group difference, even if our CPT scores were normally
distributed, we found that the significance level became
lower. In addition, the outlier in the G/A + A/A group
might drive the more significant group difference on the
commission error measure. Therefore, to eliminate some
effect of the outlier of the commission error measure, we
reanalyzed the comparison statistics of the commission
errors between two groups without the extreme scores of
the commission errors, which are considered as the out-
lier group in both group. However, the results still
showed the significant group difference on the commis-
sion error measure. Nevertheless, we will need to per-
form this correlation study in the larger sample in the
near future. Lastly, the differences in the male and female
ratio were not controlled. Majority of participants were
male in this study, and we cannot exclude the possible
effects of gender differences. In future studies, these lim-
itations should be taken into consideration to retest the
current results.
In conclusion, our study found a significant associa-
tion between commission errors of the CPT and the
G1287A genotype of the NET gene in Korean ADHD
children. The findings suggest a protective role of the
G/G genotype of the NET polymorphisms in the deficits
of response inhibition in ADHD children.
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